Anuj Bhargava
Endocrinology, Diabetes & Metabolism · Des Moines, IANPI 1669563052
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $18,003 of the $29,945 with a category attached, or 60.1%. 20 manufacturers reported payments, led by Eli Lilly at 56.4% of the total. Reporting peaked in 2023 at $15,810 and has fallen 67.4% since, to $5,161 in 2025. Among endocrinology, diabetes & metabolism clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $172.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$17K
- Sanofi-aventis U.S. LLC$6K
- Boehringer Ingelheim$3K
- Boehringer Ingelheim International GmbH$1K
- Mannkind Corporation$872
- Dexcom, Inc.$684
- plus $1K from 14 others
Across 3,348 payments — averaging $6125.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9.1M
- Medtronic$2.7M
- Dexcom, Inc.$2.5M
- Abbott$2.4M
- Novo Nordisk AS$1.1M
- AbbVie$745K
- plus $2M from 15 others
What the payments were for
- Consulting fees$2,1207%
- Speaking & faculty fees$5,27318%
- Travel & lodging$18,00360%
- Food & beverage$4,53815%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 65 | $16,903 |
| Sanofi-aventis U.S. LLC | 10 | $6,153 |
| Boehringer Ingelheim | 9 | $2,534 |
| Boehringer Ingelheim International GmbH | 11 | $1,349 |
| Mannkind Corporation | 9 | $872 |
| Dexcom, Inc. | 38 | $684 |
| Medtronic(2 entities) | 5 | $458 |
| Madrigal Pharmaceuticals | 4 | $322 |
| Ascensia Diabetes Care US Inc. | 4 | $175 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Novo Nordisk | 3 | $103 |
| AstraZeneca | 4 | $90 |
| Lilly USA, LLC | 3 | $32 |
| Abbott | 2 | $31 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$5,978
- AFREZZA$605
- MINIMED 780G$325
- REZDIFFRA$150
- DEXCOM G7 GSS (161)$125
- RESMETIROM$125
- INVOKANA$123
How this compares
$29,945 in reported general payments places this provider in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $25,223 |
| JardianceEmpagliflozin | 25 | $15,386 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $7,307 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,197 |
| NovologInsulin Aspart | 11 | $2,345 |
| Pioglitazone Hcl | 14 | $195 |
| Metformin Hcl ErMetformin Hcl | 38 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $32 | $25,22324 claims |
| Boehringer IngelheimJardiance | $2,534 | $15,38625 claims |
| Novo NordiskNovolog | $103 | $2,34511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Des Moines
- Teck KhooDes Moines$6K
- Vanitha SingaramDes Moines$824
- Pierre TheumaDes Moines$681
- Gurbir GillDes Moines$480
- Pearl DyDes Moines$430
- Daniela MilaniDes Moines$296
- Mary FigaroDavenport$73K
- Ayotunde DokunIowa City$31K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.